Generalized pustular psoriasis
MONDO:0100491A rare and extreme form of psoriasis characterized by the appearance of sterile pustules which can take many patterns. All the main pathological features of the disease are accentuated. Generalized pustular psoriasis is clinically heterogeneous in its age at onset, precipitants, severity, and natural history. Many overlapping clinical entities are recognized. There is a relationship between these entities and plaque psoriasis, as some individuals may have episodes of plaque psoriasis preceding or following the generalized pustular psoriasis, but in others generalized pustular psoriasis occurs as the sole phenotype without plaque psoriasis at any time.
41 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Can a single infusion stop GPP flares in their tracks?
Disease control OngoingThis study is testing whether the drug spesolimab can safely and effectively treat repeated flares of generalized pustular psoriasis (GPP), a serious skin condition. Adults with GPP who have had a flare will receive a single intravenous dose of spesolimab, with a possible second …
Phase: PHASE4 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill shows promise for rare, severe psoriasis
Disease control OngoingThis phase 3 trial tests an oral drug called JNJ-77242113 in 19 people with two rare and severe forms of psoriasis: generalized pustular psoriasis and erythrodermic psoriasis. The study measures how many participants see improvement after 16 weeks of treatment. It is an open-labe…
Phase: PHASE3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug shows promise for rare skin disease over nearly 5 years
Disease control OngoingThis study looks at the long-term safety and effectiveness of spesolimab in people with generalized pustular psoriasis (GPP), a rare and severe skin condition. All 131 participants had already taken spesolimab in a previous study and will continue treatment for up to 5 years. Res…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Psoriasis flare drug study pulled before it began
Disease control TerminatedThis study was designed to track the safety and effectiveness of spesolimab (Spevigo®) in Korean adults experiencing flares of generalized pustular psoriasis (GPP), a severe skin condition. The study was withdrawn before enrolling any participants, so no data were collected. It w…
Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Pharmacists take on heart disease: new study tests community-based risk reduction
Disease control OngoingThis study tests whether a pharmacist-led program can help people reduce their risk of heart disease. Over 1,000 adults with conditions like diabetes, high blood pressure, or obesity are taking part. Pharmacists use a step-by-step guide to assess risk and support lifestyle change…
Phase: NA • Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug TAK-279 targets rare, severe psoriasis in phase 3 trial
Disease control OngoingThis phase 3 trial tests the drug TAK-279 in 18 adults with generalized pustular psoriasis or erythrodermic psoriasis, two rare and severe forms of the disease. All participants receive the drug for up to 52 weeks to see if it clears skin symptoms and is safe. The study is open-l…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
NIH launches Long-Term observation of inflammatory diseases
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows up to 500 people with acute or chronic inflammatory disorders, such as infections or immune problems, over time. Researchers will monitor participants with standard tests and may screen them for other studies. The goal is to better understand these conditions a…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Scientists hunt for genetic clues in blood and urine to personalize lung cancer care
Knowledge-focused OngoingThis study collects blood, urine, and tissue samples from 330 adults with advanced lung or head and neck cancer to improve precision medicine. Researchers will analyze genetic changes in these samples and grow some tumors in mice to compare DNA. The goal is to refine liquid biops…
Phase: NA • Sponsor: University of Arkansas • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
AI vs. skin doctors: who diagnoses better?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether artificial intelligence (AI) can match a dermatologist's diagnosis when a general practitioner sends in photos and questions about a patient's skin condition. Researchers will compare the AI's diagnosis to the dermatologist's for about 1000 adults. The…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC